hypercholesterolemia/obesity

The contents of the text file named SYPA-003_C04US_SeqList_ST25.txt, which was created on Jun. 17, 2015 and is 107 KB in size, are hereby incorporated by reference in their entirety. FIELD OF THE INVENTION The present invention relates to the therapeutic use of guanylate cyclase C (GC-C) agonists as

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to the treatment of insulin related diseases, obesity, diabetes mellitus, hyperglycemia, lipid disorders, hyperlipidemia, or low HDL, hypercholesterolemia, hyperglyceridemia, dyslipidemia, and atherosclerosis. The

FIELD OF THE INVENTION The present invention relates to the therapeutic use of guanylate cyclase C (GC-C) agonists as for reducing absorption of fat, triglycerides, bile acids and cholesterol. The agonists may be used either alone or in combination with inhibitors of cholesterol biosynthesis in the

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to the treatment of insulin related diseases, obesity, diabetes mellitus, hyperglycemia, lipid disorders, hyperlipidemia, or low HDL, hypercholesterolemia, hyperglyceridemia, dyslipidemia, and atherosclerosis. The

FIELD OF THE INVENTION The present invention relates to novel "omegastatins" or `statinized` derivatives of omega-3 fatty acids used for treating hypercholesterolemia, hypertriglyceridemia, cardiovascular diseases, metabolic diseases, inflammation, or slowing down or preventing dementia of

BACKGROUND OF THE INVENTION 1. Field of the Invention The disclosed invention related to compositions and methods for the treatment of type 1 diabetes, reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia. Specifically,

FIELD OF THE INVENTION The present invention provides methods of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia,

FIELD OF THE INVENTION The present invention provides methods of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia,

FIELD OF THE INVENTION The present invention relates to methods of treating obesity, diabetes, sexual dysfunction (including erectile dysfunction), atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia, or hypertrigylceridemia using a compound that is a neurotensin

FIELD OF THE INVENTION The instant invention is concerned with acyl sulfamides and pharmaceutically acceptable salts and prodrugs thereof and their use as therapeutic. compounds, particularly in the treatment of obesity, of Type 2 diabetes mellitus (often referred to as non-insulin dependent

FIELD OF THE INVENTION This invention relates to an improved method for the reduction in a subject, vertebrate animal or human, of weight and/or body fat stores. This method involves a reduction in caloric intake, in combination with the administration of a prolactin inhibitor. In another aspect,

FIELD OF THE INVENTION This invention relates to an improved method for the reduction in a subject, vertebrate animal or human, of weight and/or body fat stores. This method involves a reduction in caloric intake, in combination with the administration of a prolactin inhibitor. In another aspect,

BACKGROUND OF THE INVENTION Field of the Invention The invention in general pertains to compositions for adipogenesis inhibition. More specifically, the present invention discloses a composition comprising scirpusin A and scirpusin Band anti-adipogenesis/anti-obesity potential thereof. Description

BACKGROUND OF THE INVENTION Field of the Invention The invention in general pertains to compositions for adipogenesis inhibition. More specifically, the present invention disposes a composition comprising scirpusin A and scirpusin B and anti-adipogenesis/anti-obesity potential thereof. Description

FIELD OF THE INVENTION The present invention relates generally to a method for the generation of a composition of matter comprised of a unique profile of primary aliphatic alcohols, having 24 to 30 carbon atoms, from a novel natural source--a wax secreted by the Chinese wax soft scale insect,